Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

Annovis Bio (ANVS) announced new data demonstrating the impact of amyloid co-pathology on cognitive outcomes in Parkinson’s patients and the therapeutic efficacy of buntanetap in this population. In the Company’s Phase 3 study in early PD, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia. Further analysis revealed that approximately 25% of them exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which was counteracted and reversed by buntanetap. These findings reinforce a central principle long championed by Annovis: neurodegenerative diseases rarely occur in isolation. Instead, multiple neurotoxic proteins-those implicated in both Alzheimer’s and Parkinson’s-drive cognitive and functional decline. Addressing this complexity requires therapies capable of targeting several toxic proteins simultaneously, which is precisely what buntanetap does. As anticipated, buntanetap treatment led to significant cognitive improvement in Parkinson’s patients with amyloid co-pathology. This response was further supported by measurable reductions in pTau217, total tau, and brain-derived tau – well-established biomarkers of neurodegeneration used in AD. Together, these findings indicate that buntanetap is actively modulating the underlying drivers of cognitive deterioration, ultimately broadening the population of patients who may benefit from treatment. “What we see is that Parkinson’s patients who experience cognitive decline also have Alzheimer’s pathology, and our drug helps them,” commented Cheng Fang, Senior VP, Research & Development. “These data are the first of its kind-no one has previously looked into treatment effects in Parkinson’s patients with amyloid co-pathology. The findings integrate seamlessly with our growing body of clinical evidence, distinguishing buntanetap as a promising therapeutic candidate for cognitive improvement across multiple neurodegenerative diseases.”